What is the starting dose of enalapril for hypertension in India?

Enalapril starting dose for hypertension: 5 mg once daily. Titrate every 2–4 weeks to target. Usual maintenance: 10–20 mg once daily (maximum 40 mg/day). In patients on diuretics, elderly, or with CKD: start at 2.5 mg once daily to avoid first-dose hypotension. Check potassium and creatinine 1–2 weeks after starting.

Why does enalapril cause a dry cough?

Enalapril (and all ACE inhibitors) inhibit the breakdown of bradykinin in the lungs, causing bradykinin to accumulate and stimulate cough receptors in the bronchi. This produces a persistent dry, irritating cough in 5–20% of patients — significantly more common in South Asian (Indian) patients than in European patients (up to 30–40% in some Indian studies). If the cough is intolerable, switching to an ARB (telmisartan, losartan, valsartan) provides equivalent blood pressure and renal protection without the cough.

Enalapril Dose Calculator India | Hypertension · Heart Failure · CKD

Enalapril Dose Calculator

Indication

eGFR (mL/min)

K⁺ (mmol/L)

Patient

Phase

Enalapril Dose

—

Tablet

—

Target dose

—

Check K⁺ + Cr

1–2 weeks after start

BP target

<130/80 mmHg

⚠️

🚫

ℹ️

💊 Drug profile

ClassACE inhibitor (prodrug → enalaprilat)

Onset1 hour (peak 4–6h)

Duration12–24h (once or twice daily)

Renal excretion~60% — dose reduce in CKD

Cough (India)Up to 30–40% South Asian patients

🏷️ Indian brands

2.5 mgEnvas 2.5 · Enam 2.5 · Enaril 2.5

5 mgEnvas 5 · Enam 5 · Enaril 5

10 mgEnvas 10 · Enam 10 · Enaril 10

20 mgEnvas 20 · Enam 20

IV 1.25mg/mlEnalaprilat inj (hypertensive emergency)

🚫 Contraindications

✗ Pregnancy (all trimesters) — fetal renal failure

✗ Bilateral renal artery stenosis

✗ K⁺ > 5.5 mmol/L before starting

✗ eGFR < 30: use with extreme caution

✗ Angioedema history (any ACEi)

⚠️ Avoid with NSAIDs — reduce renal protection

Enalapril — Clinical Guide India

Enalapril is an ACE inhibitor (angiotensin-converting enzyme inhibitor) and one of the most important cardiovascular drugs in Indian clinical practice. It is a prodrug — absorbed orally and converted to the active metabolite enalaprilat in the liver. ACE inhibitors reduce blood pressure, reduce cardiac afterload and preload in heart failure, slow progression of diabetic nephropathy, and reduce proteinuria in CKD. The CONSENSUS and SOLVD trials established enalapril's mortality benefit in heart failure. Enalapril is on the National Essential Medicines List (NEML) of India and available at very low cost.

The ACE inhibitor cough — especially important in Indian patients

ACE inhibitor-induced cough is significantly more common in South Asian (Indian, Pakistani, Sri Lankan) patients than in European patients — occurring in up to 30–40% compared to 5–15% in Western populations. This is believed to be due to genetic polymorphisms in the angiotensin-converting enzyme gene. The cough typically develops within weeks to months of starting therapy — it is a dry, persistent, tickling cough that often disturbs sleep. It is not harmful but is frequently intolerable. If cough is the only concern, switching to any ARB (telmisartan 40–80 mg, losartan 50–100 mg, valsartan 80–160 mg) provides equivalent BP lowering, HF benefit, and renal protection without cough. Never dismiss the cough as viral or unrelated to the drug without a medication review.

First-dose hypotension — how to avoid it

ACE inhibitors can cause significant first-dose hypotension, particularly in: patients on diuretics (volume depleted), elderly patients, patients with renovascular hypertension, and patients with heart failure on high-dose diuretics. Strategy: always start at the lowest dose (2.5 mg for high-risk patients); advise the first dose at bedtime; if on diuretics — hold the diuretic dose for 24 hours before the first ACE inhibitor dose; ensure patient is not volume depleted. After the first dose, check BP 1–2 hours later in high-risk patients.

Monitoring after starting enalapril — essential checks

After starting enalapril or increasing the dose: check serum potassium and creatinine/eGFR at 1–2 weeks. An acceptable rise in creatinine is up to 30% from baseline within the first 2 weeks — this reflects reduced intraglomerular pressure (the intended renoprotective mechanism) and does not warrant stopping the drug. A rise above 30% suggests significant renal artery stenosis or severe volume depletion. If K⁺ rises above 5.5 mmol/L: stop enalapril or reduce dose immediately. Inform patients not to self-discontinue for cough without informing their doctor first.

Frequently Asked Questions

Can enalapril and spironolactone be given together?+

Yes — enalapril + spironolactone is a cornerstone combination in HFrEF (established by RALES trial). However, this triple combination (ACEi + ARB is avoided; ACEi + spironolactone is acceptable) carries significant hyperkalaemia risk, especially in patients with CKD. Monitor K⁺ and creatinine at 1 week after starting or dose-adjusting either drug. Target K⁺ <5.0 mmol/L. Stop spironolactone if K⁺ exceeds 5.5 mmol/L.

Is enalapril safe in CKD?+

Yes — enalapril (and all ACE inhibitors) are specifically indicated for CKD with proteinuria or diabetic nephropathy because they reduce intraglomerular hypertension and slow progression of kidney disease, even in advanced CKD (eGFR 15–60). Start at low dose (2.5 mg OD) and titrate carefully. An initial creatinine rise of up to 30% is expected and acceptable. Avoid if eGFR <15 (expert guidance needed) or if K⁺ >5.0 mmol/L before starting. Never use in bilateral renal artery stenosis — can precipitate acute kidney failure.

⚠️Contraindicated in pregnancy. First dose at bedtime. Check K⁺ and Cr at 1–2 weeks. Stop if K⁺ >5.5 or Cr rises >30%. Switch to ARB for intolerable cough. Verify against BNF and ESC HF guidelines.

Related Tools

Amlodipine

CCB — combine for HTN

Spironolactone

HF combo — monitor K⁺

Furosemide

Loop diuretic — HF combo

eGFR Calculator

Monitor renal function